Stockholmbörsen end the week in a tendency upwards, Astra Zaneca, Bravissima and the Opus in the lead.
At 10.30-the time had storbolagsindexet OMXS30 index increased by 0.1% to 1.644. Sales stretched to over 3 billion kronor on the stockholm stock exchange.
Astra Zaneca has presented positive phase 3 results from the Pacific-study for immuniterapibehandlingen Imfinzi (durvalumab) for the treatment of non-small cell lung cancer in stage III who cannot have surgery.
”These results are very encouraging for patients with locally advanced lung cancer that cannot be treated with surgery. We look forward to working together with regulatory authorities around the world to take Imfinzi to lung cancer patients as soon as possible. In addition to this, we will examine the Imfinzis potential as a monotherapy as well as in combination with tremelimumab, and other medications in areas where there is a need for a number of cancers,” says astrazeneca’s medical director Sean Bohen as a comment to the press release.
Storägaren Bravissima has sold all of its remaining shares in Bravida for the course 61 sek. The shares dropped 2 percent to 61:55 sek.
Opus rose nearly 6% after a report that were consistently better than expected, BTS was up almost 3 per cent.
Downs: Björn Borg’s dropped around 4%, Lucara Diamond fell 1 percent after a diamantauktion and Nibe dropped 3.5 per cent or just over 3 dollars.